Search published articles


Showing 3 results for Peymani

Nasrin Goodarzi, Javid Peymani, Hasan Ashayeri, Farahnaz Meschi, Mehrdad Sabet, Mohammad-Esmaeil Akbari,
Volume 24, Issue 2 (June & July 2021)
Abstract

Background and Aim: In every age of history, human beings have been afflicted with the fear of disease. Undoubtedly, cancer is among the most concerning diseases; cancer pain is among the major pains. The present study aimed to compare the effects of cognitive-behavioral group therapy and mindfulness-based cognitive therapy on multidimensional pain symptoms in patients with breast cancer.
Methods & Materials: The present study was applied concerning the purpose and applied a quasi-experimental with pretest-posttest, a two-month follow-up, and control group design. The statistical population was all women with breast cancer referring to Tehran Cancer Research Center in 2018 who were selected by convenience sampling method, consisting of 30 patients. They were randomly divided into two groups of intervention and the control group. The repeated-measures Analysis of Variance (ANOVA) was used to analyze the obtained data. The research instrument was a multidimensional pain questionnaire (West Hyun-Yale) to evaluate multiple pain indices.
Results: The current study results suggested that cognitive-behavioral therapy and mindfulness-based cognitive therapy were effective on pain experience (P<0.001); however, there was no significant difference between the intervention groups respecting pain experience.
Conclusion Based on the present research findings, cognitive-behavioral therapy and mindfulness-based cognitive therapy impacted the management and pain intensity of patients with breast cancer.
Mojtaba Asad Samani, Maryam Peymani,
Volume 24, Issue 2 (June & July 2021)
Abstract

Background and Aim: The protein encoded by the SGO1 gene is a member of the shugoshin family of proteins and protects the centromere during mitosis. lncRNAs are non-coding RNA with 200 nucleotides lengths, i.e., involved in regulating gene expression. The current study aimed to evaluate the expression of SGO1 and SGO1-AS1 in different stages of disease progression; we also compared their expression pattern in tumor tissues with healthy tissues in colorectal cancer patients.
Methods & Materials: In total, 40 tissue samples of patients with colorectal cancer were reported according to the examination and criteria with the approval of a pathologist. Besides, 40 normal tissues were sampled from a completely healthy part of the intestine of the same patients. After RNA extraction and cDNA synthesis, the Real-time RT-PCR technique was used to evaluate the expression of the desired genes in the study groups. ROC curve analysis was also used to determine the ability of each selected gene to diagnose the disease. 
Ethical Considerations: This study was approved by the Ethics Committee of Shahrekord Azad University (Code: IR.IAU.SHKREC.1398.020).
Results The obtained data suggested that SGO1 significantly decreased in the colorectal cancer tumor samples (P<0.001) and SGO1-AS1 LncRNA significantly increased expression, compared to adjacent healthy tissues. Additionally, in the age group of below 60 years, compared to the age group of over 60 years, SGO1 expression increased and SGO1-AS1 expression decreased. Based on the AUC obtained from the ROC diagram, it was found that the SGO1 gene with AUC=0.8041 and SGO1-AS1 with AUC=0.6364 could significantly distinguish a healthy population from patients with colorectal cancer.
Conclusion: According to the collected results, SGO1 -AS1 and SGO1 were significantly reduced and increased in tumor tissue, respectively; however, only the SGO1 gene was introduced as a good marker for diagnosing colorectal cancer.

Reza Hashemi, Maryam Peymani, Kamran Ghaedi, Hana Saffar,
Volume 25, Issue 1 (April & May- 2022)
Abstract

Background and Aim PBK is a mitogen-activated protein kinase (MAPKK) among MEK1/2 and MEK7 and can phosphorylate P38, JNK, and ERK in many cellular functions. The E2F transcription factor family also belongs to a class of cellular regulators acting as oncogenes and tumor suppressors. This study aims to investigate the expression of PBK and E2F7 in the early stages of colorectal cancer (CRC) compared to advanced stages based on the experimental and TCGA (The Cancer Genome Atlas) database.
Methods & Materials A total of 32 tissue samples of patients with CRC with the approval of a pathobiologist were collected according to the examination and criteria reported from different stages. After RNA extraction and cDNA synthesis, the RT-qPCR technique was used to evaluate the expression of the desired genes in the study groups. A receiver operating characteristic (ROC) curve analysis was also used to determine the ability of each of the selected genes to differentiate the two populations: stage I+II and stage III+IV.
Ethical Considerations In all stages of this research, codes of ethics of research and publication were observed.
Results In this study, it was shown that the expression of PBK and E2F7 significantly increased in stage I+II samples compared to stage III+IV. These data were confirmed by laboratory results and information extracted from the TCGA database. Also, based on the area under curve obtained from the ROC curves, these two genes are significantly distinguishable between stage I+II and III+IV populations in CRC.
Conclusion According to the results of this study, PBK and E2F7 genes are good markers in the diagnosis of CRC.


Page 1 from 1     

© 2025 CC BY-NC 4.0 | Journal of Arak University of Medical Sciences

Designed & Developed by : Yektaweb